At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
ridaforolimus +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study of Ridaforolimus and Vorinostat in Patients With Advanced Solid Tumors or Lymphoma (IND 109130)
In Brief
A Phase 1 clinical trial evaluating ridaforolimus, vorinostat, and 3 other interventions for Lymphoma and Unspecified Adult Solid Tumor, Protocol Specific. Completed, enrolled 16 participants across 1 site.
Detailed Summary
This phase I trial is studying the side effects and best dose of giving ridaforolimus and vorinostat together in treating patients with advanced solid tumors or lymphoma. Giving ridaforolimus in combination with vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2010
Enrollment StartOct 2010
Primary CompletionMar 2014
TodayJul 2026
First PostedJul 26, 2010
Enrollment StartOct 1, 2010
Primary CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 15.9 years ago
Interventions
ridaforolimusdrug
Given PO
vorinostatdrug
Given PO
biopsyprocedure
Optional correlative studies
pharmacological studyother
Correlative studies
laboratory biomarker analysisother
Correlative studies